EyeYon, an Israeli biotech company, has just had their new therapeutic contact lens approved by the FDA.

The lens helps treat corneal edema, a common eye condition in adults that causes swelling, a build-up of fluid, blurred vision, haziness and scarring. The lenses are aimed at helping extend the time eye drops can remain in the eye in order to help alleviate symptoms of the condition which is common after cataract and corneal transplant surgeries.

“(Drops) are washed out from the center of the cornea a few seconds after the patient blinks,” Nahum Ferera, CEO of EyeYon told The Media Line. “So, this lens has a very unique design that creates a cavity above the center of the cornea that increases contact time (with the eye drop solution).”

What makes this Hyper-CL lens unique is that it has dual base curves, eight small holes, and a reservoir above the center of the cornea, which is the part of the eye that deflects light and is responsible for about a third of the eye’s optical power.

The holes in the lens enable the prescribed drops and ointments to seep into the eye under the contact lens, allowing for the extraction of excess fluids from the cornea.

“Your eye has a membrane which is a layer of cells in the cornea which pumps water out of the cornea,” Dr. Brian Marr, associate professor at Memorial Sloan Kettering and Weill Cornell Medical College in New York City told The Media Line. “The cornea is like a dry sponge and the only thing that is keeping it dry is this endothelium (membrane of cells).”

When there is too much fluid in the cornea it affects vision.

“Patients have described it as looking through ground glass or like they are in a steam room but there is no steam,” Dr. Marr added.

THe only products currently on the market to alleviate symptoms of corneal edema are a sodium chloride solution and ointment which are used by patients as they await corneal transplant surgeries.

The lens is a breakthrough, though it is not a permanent solution.

“Our lens is a palliative treatment because it doesn’t eradicate the problem, it just helps to manage it,” Dr. Ofer Daphna, EyeYon’s medical director said. “So, if a patient is on a waiting list for a corneal transplant or is suffering from chronic pain, then these patients can benefit from our contact lenses.”

Patients usually use these lenses while waiting for a corneal transplant and then use them for a month or two following the surgery, Ferara told The Media Line.

The FDA-approved lenses are currently only sold in Europe and Asia where there are about 1,000 patients using them.

“Israel has a very small market and we wanted to be very focused so we selected other territories that would be a benefit to the company,” Ferera said, adding that they are focused mainly on Asia because corneal transplants are limited there and patients need relief in the meantime.

EyeYon plans to begin marketing the 14-day disposable lenses, which cost $50 each, in the United States in 2017.